Thus, within the emerging therapeutic option of targeting the NLRP3 inflammasome as antiinflammatory strategy in CF, the finding that anakinra could have additional beneficial effects beyond NLRP3 inhibition (17) and IL-1 blockade (42) further reinforces its repurposing as a therapeutic agent in CF. Here, IL1B is linked to cystic fibrosis.